NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Recruiting in Palo Alto (17 mi)
+30 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Aptinyx
Prior Safety Data
Trial Summary
What is the purpose of this trial?A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
Eligibility Criteria
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: NYX-458 30 mgExperimental Treatment1 Intervention
Single oral dose taken daily for 12 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo Capsules
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Aptinyx Clinical SiteMiami, FL
Aptinyx Clinical SiteWest Bloomfield, MI
Aptinyx Clinical SiteHallandale Beach, FL
Aptinyx Clinical SitePort Charlotte, FL
More Trial Locations
Loading ...
Who is running the clinical trial?
AptinyxLead Sponsor
CogState Ltd.Industry Sponsor
Worldwide Clinical TrialsCollaborator